Xlumena
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Xlumena - overview
Established
2007
Location
Mountain View, CA, US
Primary Industry
Medical Devices & Equipment
About
Xlumena specializes in innovative medical technologies, particularly in the field of interventional endoscopic ultrasound (EUS) therapeutics, aimed at enhancing patient care through advanced solutions. Xlumena, founded in 2007 and headquartered in Mountain View, US, focuses on developing medical devices for endoscopic ultrasound therapies. In April 2015, the company was acquired by Boston Scientific for USD 75 mn, marking a significant pivot in its business strategy. The company has completed 9 different deals throughout its history, highlighting its active participation in the medical technology sector.
The founder's history is not provided, and there is no mention of subsidiaries or further funding rounds. Through Boston Scientific's acquisition, Xlumena provides innovative solutions in interventional endoscopic ultrasound (EUS) therapeutics. Their flagship product, AXIOS stents, facilitates minimally invasive procedures for conditions like pancreatic fluid collections and biliary obstructions, mainly utilized by healthcare professionals in hospitals and specialized medical facilities across Europe and the United States. Boston Scientific generates revenue from the direct sales of medical devices, including AXIOS stents, to healthcare providers and institutions.
The business operates on a B2B model, with pricing guided by market demands and regulatory considerations. Revenue streams are sustained by the volume of devices sold and their application in surgical procedures, ensuring a stable transaction flow with their professional clients. Xlumena's recent acquisition by Boston Scientific aims to leverage its resources for product innovation and market expansion. Although specific upcoming products are not detailed, the intention to enhance the product lineup is evident.
The company looks to expand its market presence further into regions outside its current operational territories. The USD 75 mn funding from the acquisition will likely support these strategic initiatives, although no specific plans or timelines are mentioned for new product launches or geographic expansions.
Current Investors
Prism Venture Management, Charter Life Sciences, Aperture Venture Partners
Primary Industry
Medical Devices & Equipment
Sub Industries
Therapeutic Devices
Website
www.xlumena.com
Verticals
HealthTech
Total Amount Raised
Subscriber access only

Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.